BASEL, Switzerland--(BUSINESS WIRE)--Therachon AG, a biotechnology company focused on rare genetic diseases, announced today that Jeffrey Stavenhagen, Ph.D., Vice President Biology, will be presenting at the 2nd Fibroblast Growth Factors in Development and Repair Conference in Cancun, Mexico.
Dr. Stavenhagen will present, “Development of a Novel Biologic for the Treatment of Achondroplasia” on Wednesday, March 8th from 6:35 – 6:55 PM ET. The presentation will take place at the Fiesta Americana Condesa hotel. For more information, please visit the conference’s website, here.
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. This rare genetic condition affects about one in 25,000 children and is caused by a genetic mutation of the FGFR3 receptor, which stunts child bone growth. Therachon is committed to translating the promise of its science into new treatments for patients with high unmet medical needs. For more information, visit www.therachon.com.
Visit us on TWITTER.